Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.8% – Here’s Why

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s share price fell 2.8% during trading on Wednesday . The stock traded as low as $7.37 and last traded at $7.56. 29,568 shares traded hands during trading, a decline of 55% from the average session volume of 65,741 shares. The stock had previously closed at $7.78.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ARMP. Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a research report on Monday, May 18th. HC Wainwright upped their target price on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Armata Pharmaceuticals Trading Down 2.8%

The company has a market cap of $277.53 million, a price-to-earnings ratio of -0.97 and a beta of 1.21. The firm’s fifty day moving average price is $9.75 and its 200-day moving average price is $8.40.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The firm had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.74 million. As a group, research analysts anticipate that Armata Pharmaceuticals, Inc. will post -1.88 EPS for the current year.

Hedge Funds Weigh In On Armata Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Madison Asset Management LLC acquired a new position in Armata Pharmaceuticals in the 1st quarter worth $21,583,000. 683 Capital Management LLC acquired a new position in Armata Pharmaceuticals in the 4th quarter worth $878,000. Sei Investments Co. acquired a new position in Armata Pharmaceuticals in the 1st quarter worth $760,000. Goldman Sachs Group Inc. acquired a new position in Armata Pharmaceuticals in the 4th quarter worth $284,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Armata Pharmaceuticals in the 4th quarter worth $177,000. Institutional investors and hedge funds own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.